Advent International, one of the largest and most experienced global private equity investors, today announced that it has completed its acquisition of Zentiva, Sanofi’s European generics business for €1,9 billion.
Advent is a global investor, with over 25 years’ experience of investing in the healthcare sector. It has extensive experience of executing corporate carve-outs and leveraging this expertise will support Zentiva as it enters a new phase of its history as an independent business. Advent will support the Zentiva management team to invest in the company’s operations, production facilities and R&D pipeline.
“We are delighted to have completed the acquisition of Zentiva. We believe there is tremendous potential for growth in the company and are looking forward to working with their highly talented workforce and management team to create a new, independent, European generics leader,” commented Tom Allen, Managing Director, Advent International.
“This is an important milestone for Zentiva and we are excited about the opportunities that lie ahead for us as a standalone business. We are confident that with the support of Advent we can realize our ambition to maximize our competitive advantage, expand our market footprint and upgrade our manufacturing network and capabilities. More than ever, people need better access to healthcare, that’s why we share the sense of social obligation to help lower costs and improve access to healthcare in Europe,” added Patrick Aghanian, Head of Zentiva.
Advent International’s advisers were Vienna Capital Partners, Bucéphale Finance, PJT Partners and Goldman Sachs, while Rothschild, JPMorgan Chase & Co. and Morgan Stanley advised Sanofi.
Source: Advent International/Mergermarket, 01/10/2018